259 related articles for article (PubMed ID: 29958629)
1. Therapeutic vaccines and immune checkpoints inhibition options for gynecological cancers.
Di Tucci C; Schiavi MC; Faiano P; D'Oria O; Prata G; Sciuga V; Giannini A; Palaia I; Muzii L; Benedetti Panici P
Crit Rev Oncol Hematol; 2018 Aug; 128():30-42. PubMed ID: 29958629
[TBL] [Abstract][Full Text] [Related]
2. Combination Immune Checkpoint Blockade Strategies to Maximize Immune Response in Gynecological Cancers.
Liu YL; Zamarin D
Curr Oncol Rep; 2018 Nov; 20(12):94. PubMed ID: 30421009
[TBL] [Abstract][Full Text] [Related]
3. The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer.
Shibata T; Lieblong BJ; Sasagawa T; Nakagawa M
Cancer Treat Rev; 2019 Aug; 78():8-16. PubMed ID: 31302573
[TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Inhibitors in Gynecological Cancers: Update of Literature and Perspectives of Clinical Research.
Gadducci A; Guerrieri ME
Anticancer Res; 2017 Nov; 37(11):5955-5965. PubMed ID: 29061774
[TBL] [Abstract][Full Text] [Related]
5. Update on immune checkpoint inhibitors in gynecological cancers.
Heong V; Ngoi N; Tan DS
J Gynecol Oncol; 2017 Mar; 28(2):e20. PubMed ID: 28028993
[TBL] [Abstract][Full Text] [Related]
6. Advances in the application of immune checkpoint inhibitors in gynecological tumors.
Zou Y; Xu Y; Chen X; Zheng L
Int Immunopharmacol; 2023 Apr; 117():109774. PubMed ID: 37012881
[TBL] [Abstract][Full Text] [Related]
7. From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy.
Osipov A; Murphy A; Zheng L
Adv Cancer Res; 2019; 143():63-144. PubMed ID: 31202363
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy as a treatment for biliary tract cancers: A review of approaches with an eye to the future.
Blair AB; Murphy A
Curr Probl Cancer; 2018; 42(1):49-58. PubMed ID: 29501212
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
10. Angiogenesis in gynecological cancers and the options for anti-angiogenesis therapy.
Yetkin-Arik B; Kastelein AW; Klaassen I; Jansen CHJR; Latul YP; Vittori M; Biri A; Kahraman K; Griffioen AW; Amant F; Lok CAR; Schlingemann RO; van Noorden CJF
Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188446. PubMed ID: 33058997
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy in ovarian cancer.
Krishnan V; Berek JS; Dorigo O
Curr Probl Cancer; 2017; 41(1):48-63. PubMed ID: 28169004
[TBL] [Abstract][Full Text] [Related]
12. Novel therapeutic strategies for spinal osteosarcomas.
Anwar MA; El-Baba C; Elnaggar MH; Elkholy YO; Mottawea M; Johar D; Al Shehabi TS; Kobeissy F; Moussalem C; Massaad E; Omeis I; Darwiche N; Eid AH
Semin Cancer Biol; 2020 Aug; 64():83-92. PubMed ID: 31152785
[TBL] [Abstract][Full Text] [Related]
13. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.
Gubin MM; Zhang X; Schuster H; Caron E; Ward JP; Noguchi T; Ivanova Y; Hundal J; Arthur CD; Krebber WJ; Mulder GE; Toebes M; Vesely MD; Lam SS; Korman AJ; Allison JP; Freeman GJ; Sharpe AH; Pearce EL; Schumacher TN; Aebersold R; Rammensee HG; Melief CJ; Mardis ER; Gillanders WE; Artyomov MN; Schreiber RD
Nature; 2014 Nov; 515(7528):577-81. PubMed ID: 25428507
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitors in gynecologic cancers with lessons learned from non-gynecologic cancers.
Menderes G; Hicks C; Black JD; Schwab CL; Santin AD
Expert Opin Biol Ther; 2016 Aug; 16(8):989-1004. PubMed ID: 27070175
[TBL] [Abstract][Full Text] [Related]
15. Novel approaches in cancer immunotherapy.
Subramaniam DS; Liu SV; Giaccone G
Discov Med; 2016 Apr; 21(116):267-74. PubMed ID: 27232512
[TBL] [Abstract][Full Text] [Related]
16. Gyneco-oncological genomics and emerging biomarkers for cancer treatment with immune-checkpoint inhibitors.
Curigliano G
Semin Cancer Biol; 2018 Oct; 52(Pt 2):253-258. PubMed ID: 29775688
[TBL] [Abstract][Full Text] [Related]
17. Checkpoint Inhibitors in Gynecological Malignancies: Are we There Yet?
Taha T; Reiss A; Amit A; Perets R
BioDrugs; 2020 Dec; 34(6):749-762. PubMed ID: 33141420
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.
Yang J; Chen J; Wei J; Liu X; Cho WC
Expert Opin Biol Ther; 2016 Oct; 16(10):1209-23. PubMed ID: 27426430
[TBL] [Abstract][Full Text] [Related]
19. Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine.
Zamarin D; Jazaeri AA
Gynecol Oncol; 2016 Apr; 141(1):86-94. PubMed ID: 27016233
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research.
Lee SJ; Yang A; Wu TC; Hung CF
J Gynecol Oncol; 2016 Sep; 27(5):e51. PubMed ID: 27329199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
